By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shire Pharmaceuticals Group plc 

Hampshire International Business Park
Basingstoke  Hampshire  RG24 8EP  United Kingdom
Phone: 44-1256-894-000 Fax: 44-1256-894-708



Company News
Shire Pharmaceuticals Group plc (SHPGY) To Participate At The Credit Suisse 2014 Global Healthcare Conference 11/6/2014 10:31:17 AM
The Reason Why Shire Is Moving Its HQ From Ireland To The U.K. 10/10/2014 6:37:10 AM
Shire Pharmaceuticals Group plc (SHPGY) Provides Regulatory Update On SHP 465, Investigational Compound For ADHD In Adults 10/9/2014 9:38:51 AM
Shire plc Release: Management Spurns Three Offers From AbbVie (ABBV) , Fighting For Irish Independence, Call Monday Morning 6/23/2014 12:42:43 PM
Shire Pharmaceuticals Group plc (SHPGY) To Host Investor Call 6/23/2014 7:00:26 AM
Shire Pharmaceuticals Group plc (SHPGY) Agrees To FDA Request To Conduct Clinical Trials Investigating The Potential Use of Vyvanse® (lisdexamfetamine dimesylate) In Preschool-Age Children With ADHD 6/12/2014 7:40:01 AM
Shire plc Release:” New Phase 3 Data For Guanfacine Extended Release (GXR) To Be Presented At European Congress Of Psychiatry 2/27/2014 8:30:05 AM
Shire Pharmaceuticals Group plc (SHPGY) Published Study Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII Provided Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD 8/5/2010 10:34:50 AM
Shire Pharmaceuticals Group plc (SHPGY) Initiates Two Adult ADHD Outreach Programs 8/17/2009 8:32:47 AM
Shire Pharmaceuticals Group plc (SHPGY)'s New Gaucher Drug Moves Closer to Market Following Positive Phase III Trial Results 8/3/2009 6:38:31 AM